These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 12614037)

  • 41. Treatment of Sjögren's syndrome-associated dry eye an evidence-based review.
    Akpek EK; Lindsley KB; Adyanthaya RS; Swamy R; Baer AN; McDonnell PJ
    Ophthalmology; 2011 Jul; 118(7):1242-52. PubMed ID: 21459453
    [TBL] [Abstract][Full Text] [Related]  

  • 42. General pharmacological profile of the novel muscarinic receptor agonist SNI-2011, a drug for xerostomia in Sjögren's syndrome. 4th communication: Effects on gastrointestinal, urinary and reproductive systems and other effects.
    Arisawa H; Fukui K; Imai E; Fujise N; Masunaga H
    Arzneimittelforschung; 2002; 52(4):225-32. PubMed ID: 12040964
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sjögren's syndrome: dental considerations.
    Singh M; Palmer C; Papas AS
    Dent Today; 2010 May; 29(5):64, 66-7; quiz 67. PubMed ID: 20506911
    [No Abstract]   [Full Text] [Related]  

  • 44. Sialogogic activities of SNI-2011 compared with those of pilocarpine and McN-A-343 in rat salivary glands: identification of a potential therapeutic agent for treatment of Sjörgen's syndrome.
    Iwabuchi Y; Masuhara T
    Gen Pharmacol; 1994 Jan; 25(1):123-9. PubMed ID: 7517901
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Primary Sjögren's syndrome: new clinical and therapeutic concepts.
    Ramos-Casals M; Tzioufas AG; Font J
    Ann Rheum Dis; 2005 Mar; 64(3):347-54. PubMed ID: 15498797
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Primary Sjögren's Syndrome.
    Mariette X; Criswell LA
    N Engl J Med; 2018 Mar; 378(10):931-939. PubMed ID: 29514034
    [No Abstract]   [Full Text] [Related]  

  • 47. Correlation between salivary secretion and salivary AQP5 levels in health and disease.
    Wang D; Iwata F; Muraguchi M; Ooga K; Ohmoto Y; Takai M; Mori T; Ishikawa Y
    J Med Invest; 2009; 56 Suppl():350-3. PubMed ID: 20224222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Pilocarpus in Sjogren's syndrome].
    Drøsdal HH
    Tidsskr Nor Laegeforen; 2003 Jan; 123(1):82-3. PubMed ID: 12600163
    [No Abstract]   [Full Text] [Related]  

  • 49. Inhibitory effects of muscarinic receptor autoantibodies on parasympathetic neurotransmission in Sjögren's syndrome.
    Waterman SA; Gordon TP; Rischmueller M
    Arthritis Rheum; 2000 Jul; 43(7):1647-54. PubMed ID: 10902771
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Cevimeline hydrochloride improved cholinergic dysfunction in a patient with pure autonomic failure.
    Ogata A; Kitano M; Sano H
    J Neurol; 2006 Jan; 253(1):119-20. PubMed ID: 15995794
    [No Abstract]   [Full Text] [Related]  

  • 51. RORγt antagonist suppresses M3 muscarinic acetylcholine receptor-induced Sjögren's syndrome-like sialadenitis.
    Tahara M; Tsuboi H; Segawa S; Asashima H; Iizuka-Koga M; Hirota T; Takahashi H; Kondo Y; Matsui M; Matsumoto I; Sumida T
    Clin Exp Immunol; 2017 Feb; 187(2):213-224. PubMed ID: 27643385
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cevimeline (Evoxac) for dry mouth.
    Med Lett Drugs Ther; 2000 Aug; 42(1084):70. PubMed ID: 10932302
    [No Abstract]   [Full Text] [Related]  

  • 53. AF150(S) and AF267B: M1 muscarinic agonists as innovative therapies for Alzheimer's disease.
    Fisher A; Brandeis R; Bar-Ner RH; Kliger-Spatz M; Natan N; Sonego H; Marcovitch I; Pittel Z
    J Mol Neurosci; 2002; 19(1-2):145-53. PubMed ID: 12212772
    [TBL] [Abstract][Full Text] [Related]  

  • 54. M1, M3 and M5 muscarinic receptors stimulate mitogen-activated protein kinase.
    Wotta DR; Wattenberg EV; Langason RB; el-Fakahany EE
    Pharmacology; 1998 Apr; 56(4):175-86. PubMed ID: 9566019
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cevimeline gargle for the treatment of xerostomia in patients with Sjögren's syndrome.
    Takagi Y; Kimura Y; Nakamura T
    Ann Rheum Dis; 2004 Jun; 63(6):749. PubMed ID: 15140789
    [No Abstract]   [Full Text] [Related]  

  • 56. Salivary enhancement: current status and future therapies.
    Atkinson JC; Baum BJ
    J Dent Educ; 2001 Oct; 65(10):1096-101. PubMed ID: 11699983
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cevimeline co-treatment attenuates olanzapine-induced metabolic disorders via modulating hepatic M3 muscarinic receptor: AMPKα signalling pathway in female rats.
    Han M; Lian J; Su Y; Deng C
    J Psychopharmacol; 2022 Feb; 36(2):202-213. PubMed ID: 34694173
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Cevimeline (Evoxac ®) overdose.
    Voskoboynik B; Babu K; Hack JB
    J Med Toxicol; 2011 Mar; 7(1):57-9. PubMed ID: 20865466
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Polysaccharides of Dendrobium officinale induce aquaporin 5 translocation by activating M3 muscarinic receptors.
    Lin X; Liu J; Chung W; Sze SC; Li H; Lao L; Zhang Y
    Planta Med; 2015 Jan; 81(2):130-7. PubMed ID: 25590366
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Reduction of cerebrospinal fluid amyloid beta after systemic administration of M1 muscarinic agonists.
    Beach TG; Walker DG; Potter PE; Sue LI; Fisher A
    Brain Res; 2001 Jun; 905(1-2):220-3. PubMed ID: 11423097
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.